Whole-exome sequencing has been incredibly successful in identifying causal genetic variants and has revealed a number of novel genes associated with blood and other diseases. One limitation of this approach is that it overlooks mutations in noncoding regulatory elements. Furthermore, the mechanisms by which mutations in transcriptional cis-regulatory elements result in disease remain poorly understood. Here we used CRISPR/Cas9 genome editing to interrogate three such elements harboring mutations in human erythroid disorders, which in all cases are predicted to disrupt a canonical binding motif for the hematopoietic transcription factor GATA1. Deletions of as few as two to four nucleotides resulted in a substantial decrease (>80%) in target gene expression. Isolated deletions of the canonical GATA1 binding motif completely abrogated binding of the cofactor TAL1, which binds to a separate motif. Having verified the functionality of these three GATA1 motifs, we demonstrate strong evolutionary conservation of GATA1 motifs in regulatory elements proximal to other genes implicated in erythroid disorders, and show that targeted disruption of such elements results in altered gene expression. By modeling transcription factor binding patterns, we show that multiple transcription factors are associated with erythroid gene expression, and have created predictive maps modeling putative disruptions of their binding sites at key regulatory elements. Our study provides insight into GATA1 transcriptional activity and may prove a useful resource for investigating the pathogenicity of noncoding variants in human erythroid disorders.
Whole-exome sequencing has been incredibly successful in identifying causal genetic variants and has revealed a number of novel genes associated with blood and other diseases. One limitation of this approach is that it overlooks mutations in noncoding regulatory elements. Furthermore, the mechanisms by which mutations in transcriptional cis-regulatory elements result in disease remain poorly understood. Here we used CRISPR/Cas9 genome editing to interrogate three such elements harboring mutations in human erythroid disorders, which in all cases are predicted to disrupt a canonical binding motif for the hematopoietic transcription factor GATA1. Deletions of as few as two to four nucleotides resulted in a substantial decrease (>80%) in target gene expression. Isolated deletions of the canonical GATA1 binding motif completely abrogated binding of the cofactor TAL1, which binds to a separate motif. Having verified the functionality of these three GATA1 motifs, we demonstrate strong evolutionary conservation of GATA1 motifs in regulatory elements proximal to other genes implicated in erythroid disorders, and show that targeted disruption of such elements results in altered gene expression. By modeling transcription factor binding patterns, we show that multiple transcription factors are associated with erythroid gene expression, and have created predictive maps modeling putative disruptions of their binding sites at key regulatory elements. Our study provides insight into GATA1 transcriptional activity and may prove a useful resource for investigating the pathogenicity of noncoding variants in human erythroid disorders.
GATA1 | cis-regulatory elements | noncoding mutations | Mendelian erythroid disorders W hole-exome sequencing (WES) and targeted sequencing approaches have greatly accelerated our ability to identify causal genetic lesions in both previously implicated and novel genes underlying monogenic disorders (1, 2) . In hematology, WES has been extremely useful for identifying unknown genetic etiologies for various disorders, such as those affecting red blood cell (RBC) production, including Diamond-Blackfan anemia and congenital dyserythropoietic anemia (3) (4) (5) , disorders of RBC structure and function (6, 7) , and disorders affecting other aspects of hematologic function (2, 8) . Despite this considerable success, however, more than 50% of cases of presumed monogenic diseases are refractory to current WES approaches (9) . Although resolving these remaining cases will benefit from improvements in exome capture (10) , read alignment (11) , and variant annotation methodologies (11), the importance of genetic variation occurring within regulatory elements (REs) outside of the traditionally investigated coding sequences in hematologic and other diseases is being increasingly appreciated (12) .
Whole-genome sequencing (WGS) approaches are becoming progressively more available and affordable, but separating pathogenic genetic variation from benign or unrelated mutations remains especially difficult outside of protein-coding genetic regions (12, 13) . This difficulty is most clearly reflected in the distribution of mutations listed in databases of Mendelian disorders, such as the Human Gene Mutation Database, where most mutations are found within coding regions (86%) or at intronic splice sites (11%), with only a small fraction (3%) identified in regulatory regions (14) . Newer methods for annotating and predicting the impact of noncoding (NC) variants have provided substantial improvements (15, 16) , but experimental validation of the presumed effects remains critical for the determination of pathogenicity and elucidation of the mechanism of action (13, 17) .
Multiple lines of evidence have shown that NC mutations can modulate the transcriptional activity and binding of key cell typespecific master transcription factors (TFs) (18, 19) . In several Mendelian erythroid disorders (MEDs), NC genetic variants have been identified in the DNA-binding motif (WGATAR) of the hematopoietic master regulator, GATA1 (20) (21) (22) (23) (24) (25) . GATA1 is both necessary for proper erythropoiesis (3, 26) and sufficient to reprogram alternative lineages toward an erythroid fate (27, 28) . Moreover, numerous studies have shown that GATA1 acts in a
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number of multimeric complexes involving other TFs and can activate or repress target gene expression (29) (30) (31) (32) (33) (34) (35) (36) (37) .
Although much has been learned about transcriptional regulation during erythropoiesis, the determinants of GATA1 activity at individual REs are incompletely understood (29) . For example, after Gata1 induction in the Gata1-null G1E-ER4 erythroblast (EB) cell line, GATA1 binds to and up-regulates key erythroid genes to induce terminal erythroid differentiation, while simultaneously repressing genes involved in alternative lineages. The global chromatin architecture is indistinguishable between induced and repressed genes, however, suggesting that additional features, such as DNA sequence requirements and combinatorial TF patterns, determine the resulting transcriptional alterations in this model system and also more generally during lineage commitment and differentiation (29-31, 34, 35, 37-42) . Furthermore, the effects of genetic variation on erythroid cis-regulatory elements (CREs), particularly with regard to those predicted to disrupt GATA1 or cofactor (CF) motifs on GATA1 and CF binding and target gene expression, are not well defined (40) .
Given these deficiencies, we interrogated three regions harboring rare variants implicated in distinct MEDs that are predicted to disrupt GATA1 motifs, using a combination of experimental and computational approaches to gain further insight into GATA1 transcriptional activity (20) (21) (22) (23) 43) .
Results
Using Genome Editing to Verify NC Mutations Implicated in MEDs. We selected single nucleotide mutations implicated in X-linked sideroblastic anemia (XLSA) (21, 22) , congenital erythropoietic porphyria (CEP) (20) , and pyruvate kinase deficiency (PKD) (23, 43) that were predicted to disrupt a GATA1 binding site (BS) (Fig. S1 ). In each case, the mutation fell within an erythroid CRE occupied by GATA1 and multiple CFs proximal to the known causal gene (ALAS2 in XLSA, UROS in CEP, and PKLR in PKD) ( Fig. 1 A-C) . To verify the effects of each NC mutation, we used CRISPR/Cas9 genome editing to create precise doublestranded DNA breaks across the affected core "GATA" motif in the K562 erythroid cell line, which shares a similar regulatory architecture at these CREs with primary human EBs ( Fig. S2 ) (32) . We used a PCR-based screen to identify three to four clones with small deletions ranging in size from 2 to 15 nt across each motif resulting from unfaithful repair of the targeted double-stranded DNA breaks (Fig. S3) .
For clonal GATA1 motif deletions in the intronic CREs of ALAS2 and UROS, we observed an ∼80% reduction of ALAS2 and UROS mRNA, but for clonal deletions in the PKLR promoter, we observed a >99% reduction of PKLR mRNA (Fig.  1D) . Deletions of as little as 2 nt were sufficient to reduce target mRNA transcription by >80%, similar to findings in reporter assays (20, 44) . Although these results verify the functionality of the selected mutations, they also suggest that not all GATA1 BS variants will affect gene expression equally. In our experiments, GATA1 motif deletion in a promoter resulted in complete abrogation of target gene expression, whereas residual target mRNA expression was still detectable in deletions at intronic CREs. In addition, secondary intronic CREs occupied by GATA1 and TAL1 within ALAS2 and UROS may additively regulate gene expression; no secondary CREs were detected near PKLR ( Fig. 1 A-C) .
As a proof of principle that this approach can validate variants in a disease-relevant context, we used a lentiviral CRISPR/Cas9 approach to target these GATA1 motifs in adult CD34
+ hematopoietic stem and progenitor cells (HSPCs). By targeting the CRE proximal to ALAS2, we observed a specific reduction in ALAS2 mRNA expression; we obtained similar results by targeting the CRE proximal to UROS (Fig. 1E) . Importantly, the Cas9-infected HSPCs showed no impairment in their ability to undergo robust erythroid differentiation (Fig. 1F ).
Isogenic Cellular Models Phenocopy Cell-Intrinsic Effects of Associated
Disorders. We next set out to determine the extent to which our cellular models of NC GATA1 BS mutations could phenocopy the cell-intrinsic effects of each associated MED. In XLSA, mutations in ALAS2, the gene encoding for δ-aminolevulinic acid synthase 2, the rate-limiting enzyme in heme biosynthesis, result in decreased heme production, promoting formation of the characteristic ringed sideroblasts ( Fig. 2A) . Thus, we performed a heme quantification assay and verified a decrease in heme levels of ∼40% in our XLSA model compared with isogenic controls ( Fig. 2A, Right) . Residual heme production is likely attributable to the small amount (∼20%) of ALAS2 mRNA expression and the moderate levels of the ubiquitously expressed δ-aminolevulinic acid synthase 1 (encoded by ALAS1) in the cells (Fig. S4) .
Similar to XLSA, CEP is also a disorder of dysregulated heme biosynthesis. Although mutations in UROS, the gene encoding uroporphyrinogen III synthase, also result in mildly reduced heme production, the phototoxicity and hemolysis observed in CEP are attributable primarily to accumulation of the toxic nonphysiological coproporphyrin I isomers (Fig. 2B) (20) . To measure this accumulation in our CEP model, we performed a porphyrin assay, and found that our CRISPR-edited clones had an approximately fourfold higher ratio of isomer I to isomer III porphyrins compared with controls (Fig. 2B, Right) .
Finally, we investigated our cellular models of PKD, one of the most common causes of hereditary nonspherocytic hemolytic anemia (D) Relative mRNA expression levels of ALAS2, UROS, and PKLR across clonal deletions of the associated GATA1 BS. ****P < 0.0001. (E) Relative mRNA expression levels of ALAS2 and UROS on day 10 of differentiation with a vector containing Cas9 and a nontargeting sgRNA (black; sgXPR5) or sgRNAs targeting the GATA1 motif in the CRE near ALAS2 (red; sgALAS2) or near UROS (orange, sgUROS). *P < 0.05; **P < 0.01; n.s., P nonsignificant.
(F) CD235a expression at day 12 of differentiation in infected HSPCs. Unstained control cells are shown in gray.
(45). Pyruvate kinase (PK), encoded by PKLR, catalyzes the final reaction of glycolysis by converting phosphoenolpyruvate to pyruvate (Fig. 2C , Top Left). We first measured intracellular levels of mature PKLR protein and confirmed a reduction in our CRISPR-edited clones (Fig. 2C , Bottom Left). Nevertheless, a PK enzymatic activity assay revealed only weakly to moderately reduced activity in the CRISPR-edited clones compared with controls ( Fig. 2C , Top Right). Interestingly, although PKLR is the only PK expressed in the committed erythroid lineage in humans, K562 cells strongly express PKM, an alternative PK, suggesting that even though PKLR is nearly absent in our PKD model, PKM alone is able to sustain glycolysis (Fig. 2C , Bottom Right). Overall, by disrupting specific GATA1 BSs, our cellular models are able to mimic the cell-intrinsic effects of XLSA, CEP, and PKD to varying degrees.
Targeted Disruption of the Core GATA Motif Destabilizes GATA1 TF Complexes. As a master regulator of erythropoiesis, GATA1 often acts in a multimeric complex comprising TAL1 as well as the non-DNA-binding TFs LMO2 and LDB1, which can loop from CRE to promoter to regulate gene expression (33, (35) (36) (37) . Mutations in the TAL1 motif (occurring 8-9 nt from a GATA1 motif) have been shown to modulate gene expression by significantly displacing both TAL1 and LDB1 while exhibiting only marginal effects on GATA1 binding (40) . Although we have shown that mutations in the GATA1 motif itself can affect target gene expression, resulting in disease, little is known about how these mutations affect binding of the entire activation complex. Thus, we selected clones with the smallest GATA1 motif deletions (maximum 4 nt) and performed ChIP followed by PCR (ChIP-PCR) for TAL1, the other DNA-binding component of the multimeric complex (whose canonical motif was not disrupted). Interestingly, all three GATA1 mutations resulted in a complete loss of TAL1 binding compared with both the GFP control and cross-isogenic control cells (Fig. 3 A-C) . Thus, we provide direct evidence for a previously proposed model in which both TAL1 and GATA1 binding are important for proper erythroid gene expression, TAL1 binding is dependent on GATA1 (37, 46), but GATA1 binding appears to be only partially dependent on TAL1 (Fig. 3D ) (40) . (9, 44, 47, 48) . This suggests the possibility that an important minority of causal genetic lesions may instead be located within NC regulatory regions. Given that we have verified that mutations identified in GATA1 BSs are pathogenic for three distinct MEDs, we wanted to investigate these BSs for other MEDs in which the known genetic defects act intrinsically within the erythroid lineage (www.bloodgenes.org/MEDs.html). We first enumerated all CREs occupied by GATA1 in primary human EBs that are proximal to the ∼20 known pathogenic MED genes. Within these CREs, we identified 176 core GATA sites, and investigated the evolutionary conservation of these four nucleotides as a proxy for functionality (32, 44, 47, 48) . Surprisingly, although we observed only slight conservation for the GATA site within all ∼20,000 GATA1 chromatin occupancy sites across the genome, GATA sites within MED CREs were substantially conserved (Fig.  4A) (32) . Moreover, the region containing the TAL1 motif 8-9 nt upstream of the core GATA motif was specifically conserved in a subset of MED CREs, suggesting the importance and functionality of both factors at these elements (Fig. 4B) (37) . Therefore, we suggest that GATA1, and in certain cases TAL1, DNA BSs may harbor mutations in MED cases without identifiable and pathogenic genetic lesions within the coding sequence of the known MED genes.
To experimentally verify that disruption of these GATA1 motifs could affect expression of the target MED genes, we performed CRISPR/Cas9 genome editing at GATA1 motifs within seven CREs proximal to four MED genes. For five of the seven targeted CREs, we observed a significant decrease in target gene expression (ranging from ∼30% to 80%) (Fig. 4 C-F and Fig. S5 ). (Interestingly, we observed that targeting the other two CREs resulted in increased mRNA expression of the target gene, SLC4A1.) Because we measured mRNA expression only in bulk cells, this finding is likely an underestimation of the true effect of the GATA1 motif disruption. Interestingly, GATA1 appears to regulate genes implicated in disorders of the RBC membrane ALAS2 is the rate-limiting enzyme in this pathway, and its disruption leads to decreased heme production. (Right) Relative amounts (in μM) of heme normalized to cell number. ****P < 0.0001. (B) (Left) Schematic of the extracellular portion of the heme biosynthesis pathway. δ-aminolevulinic acid is stepwise converted to hydroxymethylbilane, which is then synthesized into uroporphyrin III by UROS, eventually resulting in heme production. Without UROS, hydroxymethylbilane is processed into nonphysiological isomer I porphyrins, resulting in hemolysis and UV phototoxicity. (EPB41 and KCNN4), various enzyme-related diseases (PKLR and HK1), and disorders occurring within the heme biosynthetic pathway (ALAS2 and UROS), suggesting that mutations in GATA1 BSs may occur in a number of distinct MEDs.
Understanding and Predicting the Effects of NC Mutations on GATA1
and CFs. Finally, we aimed to gain a better global understanding of the combinatorics of erythroid transcriptional regulation and to identify the important DNA elements underlying these TFs (31-33, 38, 39, 41) . To do so, we first used ChIP-seq to define the relative binding of GATA1 and four CFs generally implicated in an activation complex with GATA1: TAL1, LDB1, KLF1, and NFE2 (31-35, 37, 39) . Modeling the relative binding intensities of these CFs across the proximal promoters of ∼18,000 genes revealed that these five factors alone explained 46% of the variation in proerythroblast (proE) gene expression (Fig. 5A) .
We next investigated combinatorial binding patterns using partitioning around medoids (PAM), and identified six clusters of variable combinations of binding by GATA1 and CFs (Fig. 5B  and Fig. S6 ). The first five clusters exhibited concomitant GATA1, TAL1, KLF1, and NFE2 binding intensity, associated with increasing expression during terminal erythroid differentiation (Fig. 5C) . Interestingly, cluster 6 was differentiated from the other clusters by substantially greater LDB1 and TAL1 promoter binding, greater LDB1 binding at distal CREs (Fig. S7) , and stronger transcriptional induction during terminal erythropoiesis (Fig. 5 B and C) (35) . In addition, many MED genes, as well as the erythroid TFs themselves, were found within clusters with strong erythroid TF intensity (Fig. 5C ). Building on previous work (31-33, 38, 39, 41) , our results provide additional evidence that the cooperation of these five TFs is important for the proper expression of key erythroid genes, such as those mutated in MEDs.
Given the importance of multiple TFs in our model, we dissected the DNA elements of CREs at the known MED genes using two state-of-the-art approaches to predict the cell typespecific effects of NC mutations. First, we trained a gapped k-mer support vector machine (gkmer-SVM) on EB and K562 open chromatin data and used delta-SVM to predict single nucleotide effects (16) . We then used already-trained models for the TFs GATA1, TAL1, KLF1, and NFE2 from DeepBind, a convolutional neural network approach (15) . For each CRE proximal to the 20 MED genes, we created a "mutation map" of the predicted effects of all possible single nucleotide changes (15) .
For each GATA1 motif that we functionally verified with CRISPR/Cas9 genome editing, our models show that a single nucleotide change in the core GATA is predicted to completely abolish binding, consistent with our in vitro results and the in vivo phenotypes in patients with cis-regulatory mutations (Fig. 5D and Fig. S8) . Moreover, the mutation maps suggest that TAL1 binding is more strongly affected by alterations to the GATA1 motif than by alterations to its own motif, consistent with our TAL1 ChIP-PCR results (Fig. 5D and Fig. S8 ). To further demonstrate the utility of our mutation maps, we determined that mutations reported in two independent cases of PKD (in what was previously known as the PKLR-RE1 element) actually disrupted the TAL1 , and the PKLR promoter (C). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., P nonsignificant. (D) Model of mutations in a standard activation complex involving GATA1. (A) Conservation of GATA1 binding motifs using PhastCons scores. Low-level conservation is observed across ∼40,000 GATA1 motifs within all ∼20,000 GATA1 occupancy sites in EBs (blue). Strongly conserved GATA1 motifs with biochemical activity for GATA1, TAL1, and KLF1 (CGTK) in human and mouse EBs are positive controls (red). The 176 GATA1 binding motifs in CREs occupied by GATA1 proximal to MED genes (green) are conserved, suggesting that they are functional. (B) Conservation across the 176 GATA1 motifs shown in A. Approximately 40% of these GATA1 binding motifs are strongly conserved, and ∼60% of these are co-conserved with TAL1 motifs. Black lines separate clusters identified using k-means. (C) ChIP-seq profiles across EPB41, similar to those shown in Fig. 1 A-C. E1 and E2 are GATA1 motifs in CREs occupied by GATA1 that we targeted using CRISPR/Cas9. (D) Relative mRNA expression levels of EPB41. ****P < 0.0001. (E) ChIP-seq profiles across KCNN4, similar to those shown in C. K1 is a GATA1 motif similar to E1.
(F) Relative mRNA expression levels of KCNN4. ****P < 0.0001.
motif proximal to the interrogated GATA1 motif (Fig. 5D ) (49, 50) , highlighting the important role of GATA1 CFs in regulating proper gene transcription during erythropoiesis (33, 40) . We also observed multiple "complex" REs containing multiple TF binding motifs. For example, at a CRE occupied by GATA1, TAL1, KLF1, LDB1, and NFE2 in the eighth intron of ALAS2, our mutation maps identified multiple GATA1 and TAL1 motifs, as well as a KLF1 motif and an NFE2 motif (Fig. 5E ). Exogenous reporter assays have shown that, depending on the exact "chunks" of DNA tested, this region can vary in activation strength and even repress (51) . Intriguingly, when we separately targeted two GATA1 motifs in ALAS2 intron 8 with CRISPR/Cas9, we observed an increase in ALAS2 mRNA expression, similar to the results obtained by targeting two CREs near SLC4A1, suggesting that these regions may have a particularly complex regulatory architecture (Fig.  S9) (51) . Taken together, our analyses provide additional evidence that erythroid CREs are dependent on the binding of multiple TFs for proper transcriptional regulation and RBC development. We provide visualizations of the regulatory landscape of MED genes, gene expression graphs, and mutation maps across CREs for each MED on our website (www.bloodgenes.org/MEDs.html).
Discussion
In this study, we interrogated natural genetic variations occurring in MEDs to provide a window into the functions of erythroid gene regulatory networks (2) . In primary HSPCs and an erythroid cell line, we used CRISPR/Cas9 genome editing to verify the regulatory effects of NC genetic variants associated with XLSA, CEP, and PKD, and were able to recapitulate the cellintrinsic phenotypes of the associated disorder (20) (21) (22) (23) 43) . These immortalized cellular models are readily available for the study of disease pathology and may prove useful for screening potential treatments, such as gene therapy (52) . More generally, our approach to experimentally validate the pathogenicity of rare NC variants can be applied to novel NC variants associated with erythroid or nonerythroid Mendelian diseases.
During the process of functionally verifying the selected mutations, we determined that small alterations (2-4 nt) of a GATA1 motif were sufficient to reduce expression of the known causal gene by >80% in all cases; although the exact effects of each single nucleotide variant observed in vivo remains to be shown. Mechanistically, we showed that by solely disrupting the GATA1 BS at a CRE, the binding of the DNA-binding CF TAL1 is severely impaired, likely resulting in loss of the entire CF-containing multimeric complex (35, 37) . Our analysis of combinatorial occupancy patterns of erythroid TFs highlights the importance of this multimeric complex formed by GATA1, TAL1, and LDB1 for the induction of key erythroid genes during terminal erythropoiesis (33, 41) . In contrast to the GATA1 BSs interrogated here, our predictive maps and other studies have shown that mutations in TAL1 BSs have only marginal effects on GATA1 binding, while still resulting in altered gene expression (40) .
Another important finding from the present study is that similar GATA1 motif deletions did not always result in a complete abrogation of target gene expression. Although more examples are needed to confirm the exact principles and extent of context dependence (i.e., promoter vs. intronic/distal CRE), our results primarily suggest the possibility of enhancer additivity. Our investigation of multiple CREs proximal to EPB41, HK1, ALAS2, and SLC4A1 showed that each CRE independently regulated the expression of its target gene.
Finally, determining the pathogenicity and/or causality of NC genetic variants that either result in disease or modify disease severity remains difficult (13, 53) . To address this, we coupled experimental and bioinformatics approaches to show that mutations in GATA1 and CF BSs can substantially affect genes implicated in MEDs, and created mutation maps of predicted mutations across CREs proximal to MED genes (15, 16) . These maps may prove useful for prioritizing variants from WGS or targeted sequencing of MED cases, as we have initially shown for PKLR-RE1 mutations that disrupt a TAL1 binding motif, and can identify disruptive as well as gain-of-function mutations. Nevertheless, our maps might not represent all regulatory modalities, such as the effects of currently unassayed TFs or complex REs (i.e., barrier insulators) (54) . Furthermore, experimental validation of an associated variant (using, e.g., CRISPR/Cas9 genome editing) remains the cornerstone for determining causality (13) . Altogether, our combined approach for interrogating NC genetic variation reveals important aspects of both GATA1 transcriptional activity and erythroid CREs, and likely will prove useful for identifying and dissecting NC mutations in MEDs.
Materials and Methods
Experimental Outline. K562 cells were cotransfected with Cas9 nuclease and sgRNA plasmids and subjected to puromycin selection and limiting dilutions. Clones were screened for small deletions of the WGATAR motif via PCR, and successful clones were selected for downstream assays. The experimental procedures are described in detail in SI Materials and Methods.
Bioinformatic and Statistical Analyses. Unless specified otherwise, the twotailed Student t test was used for comparisons between groups. ChIP-seq and RNA-seq were processed as described previously (32) . Random forests were used to model expression, k-means and PAM were used for clustering, and gkmer-SVM and DeepBind were used to create mutation maps (15, 16) . Complete details are available in SI Materials and Methods. 
